Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$56.23 USD
+0.26 (0.46%)
Updated Jul 26, 2024 04:00 PM ET
After-Market: $56.21 -0.02 (-0.04%) 7:58 PM ET
1-Strong Buy of 5 1
B Value B Growth D Momentum B VGM
Brokerage Reports
Halozyme Therapeutics, Inc. [HALO]
Reports for Purchase
Showing records 1 - 20 ( 197 total )
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Second ENHANZE Approval in a Week; OCREVUS SC EU Mandate; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Another ENHANZE Win; VYVGART Hytrulo Gets CIDP Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Patent Boosts EU Darzalex SC Royalty; Guidance Improved; Raising PT to $65
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Another Enhanze Win Via Subcutaneous RYBREVANT Data at ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Accelerated U.S. Approval Decision Date for Opdivo SC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Financial Results; Long-Term Guidance Reaffirmed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Opdivo SC Coming Soon; Wave 3 Execution; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
European Agency Recommends OCREVUS SC For Approval; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Pivotal OCREVUS SC Data; Expect Approvals in 2024; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q24 Earnings Preview; Model Adjustments to Reflect Revenue Cadences; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: KAPOOR M
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Halozyme Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department